Salvage Yttrium-90 Transarterial Radioembolization Combined with Second-Line Molecular Targeted Agents and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Progressing After TACE-Based Combination Therapy: A Single-Center Real-World Study

Background

Patients with hepatocellular carcinoma (HCC) that progresses after first-line transarterial chemoembolization (TACE) combined with molecular targeted agents (MTAs) and immune checkpoint inhibitors (ICIs) have limited therapeutic options. This single-center, retrospective, single-arm real-world study evaluated the efficacy and safety of salvage yttrium-90 transarterial radioembolization (Y-90 TARE) plus second-line systemic therapy in this population.